Cargando…

The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 ((177)Lu)-lilotomab (Betalutin(®)) was investigated in preclinical mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichard, Alexandre, Marcatili, Sara, Karam, Jihad, Constanzo, Julie, Ladjohounlou, Riad, Courteau, Alan, Jarlier, Marta, Bonnefoy, Nathalie, Patzke, Sebastian, Stenberg, Vilde, Coopman, Peter, Cartron, Guillaume, Navarro-Teulon, Isabelle, Repetto-Llamazares, Ada, Heyerdahl, Helen, Dahle, Jostein, Bardiès, Manuel, Pouget, Jean-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192854/ https://www.ncbi.nlm.nih.gov/pubmed/31836849 http://dx.doi.org/10.1038/s41375-019-0677-4

Ejemplares similares

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
por: Stokke, Caroline, et al.
Publicado: (2018)

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2015)

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
por: Malenge, Marion M., et al.
Publicado: (2022)

FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?
por: Løndalen, Ayca, et al.
Publicado: (2022)

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
por: Løndalen, Ayca, et al.
Publicado: (2020)

Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H V, et al.
Publicado: (2013)

Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects
por: Paillas, Salomé, et al.
Publicado: (2016)

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014)

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2019)

(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
por: Giesen, Danique, et al.
Publicado: (2022)

Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [(177)Lu-[DOTA0, Tyr3]-octreotate
por: Santoro, Lore, et al.
Publicado: (2018)

Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting (227)Th-DOTA-p-benzyl-trastuzumab
por: Heyerdahl, Helen, et al.
Publicado: (2012)

Experimental α-particle radioimmunotherapy of breast cancer using (227)Th-labeled p-benzyl-DOTA-trastuzumab
por: Abbas, Nasir, et al.
Publicado: (2011)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

Revisiting the Radiobiology of Targeted Alpha Therapy
por: Pouget, Jean-Pierre, et al.
Publicado: (2021)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
por: Rødland, Gro Elise, et al.
Publicado: (2019)

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate (212)Pb-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2020)

Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway
por: Constanzo, Julie, et al.
Publicado: (2021)

Clinical implementation of PLANET® Dose for dosimetric assessment after [(177)Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0
por: Santoro, Lore, et al.
Publicado: (2021)

Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using (2) (1) (2)Pb
por: Boudousq, Vincent, et al.
Publicado: (2013)

Ceramide-Enriched Membrane Domains Contribute to Targeted and Nontargeted Effects of Radiation through Modulation of PI3K/AKT Signaling in HNSCC Cells
por: Ladjohounlou, Riad, et al.
Publicado: (2020)

Peptides in Receptor-Mediated Radiotherapy: From Design to the Clinical Application in Cancers
por: Lozza, Catherine, et al.
Publicado: (2013)

Introduction to Radiobiology of Targeted Radionuclide Therapy
por: Pouget, Jean-Pierre, et al.
Publicado: (2015)

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
por: Ashraf, Yahya, et al.
Publicado: (2019)

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells
por: Estupina, Pauline, et al.
Publicado: (2017)

Bystander effects in UV-induced genomic instability: Antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation
por: Dahle, Jostein, et al.
Publicado: (2005)

An Experimental Generator for Production of High-Purity (212)Pb for Use in Radiopharmaceuticals
por: Li, Ruth Gong, et al.
Publicado: (2023)

Challenges and Risks in Out-of-Hospital Transport of Patients During the Coronavirus Disease 2019 Pandemic
por: Rehn, Marius, et al.
Publicado: (2023)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

In situ Generated (212)Pb-PSMA Ligand in a (224)Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-Positive Cells
por: Stenberg, Vilde Y., et al.
Publicado: (2020)

Subject index for volume 177
Publicado: (1990)

Health Tract, No. 177: Cancer
Publicado: (1863)

Health Tract, No. 177: Cancer
Publicado: (1865)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Juzeniene, Asta, et al.
Publicado: (2021)

Comparison of three regimens with inhalational methoxyflurane versus intranasal fentanyl versus intravenous morphine in pre-hospital acute pain management: study protocol for a randomized controlled trial (PreMeFen)
por: Simensen, Randi, et al.
Publicado: (2023)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome
por: D’Hondt, Véronique, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1scus70r36q880dj8p7o9veto3